Join Community
Join Community
POLYCYTHEMIA VERA

Know your options. Shape your care.

Watch the free expert program on PV treatment, then download the PV Webinar Toolkit built from it. The toolkit will help you understand your risk category, the symptoms and lab results to track, and provide an overview of the treatment options covered.

Jennifer Vaughn, MD, MSPH, Associate Professor of Hematology, The Ohio State University Comprehensive Cancer Center – The James, with Nick Napolitano, PV patient advocate, diagnosed in 2016

Free to watch and downloadOn demand now, recorded Oct. 14, 2026Toolkit emailed to every registrant

The Patient StoryPV TOOLKIT

Program toolkit, PV treatment today

Your PV Toolkit starts here

Toolkit page: Treatment Options, taken from our interview with Dr. Vaughn, with summaries of phlebotomy, aspirin, hydroxyurea and ropeginterferon
  • The full program, on demand, with Dr. Vaughn and Nick Napolitano
  • The 6-page PV Toolkit, printable and emailed to you

Next, choose On demand to watch now or Replay to get a link by email.

Free. For general education only, not medical advice.1

In the program

Six questions Dr. Vaughn answers

Am I low-risk or high-risk?

How doctors decide your risk of a blood clot (thrombosis), and why that category shapes your treatment.

Why is PV considered a cancer?

PV is a chronic blood cancer, one of the myeloproliferative neoplasms (MPNs). Dr. Vaughn explains what’s happening in your bone marrow, and what that word does and doesn’t mean for your outlook.

What labs should I track?

Hematocrit, hemoglobin, white cells, platelets, ferritin and more: what each one measures and why it matters in PV.

How do I start tracking symptoms to make my appointments better?

From fatigue and itching to night sweats and brain fog, how to log what you notice and turn it into a better conversation with your care team.

How do I bring this up in a short appointment?

Practical language for symptoms, cost concerns and quality-of-life questions.

What are my treatment options today?

Phlebotomy and aspirin, hydroxyurea, interferon therapy and the newest FDA-approved option, explained side by side.

From the toolkit

Dr. Vaughn explains which counts matter between visits. The toolkit’s lab tracker gives you one place to log them, outside labs included, so you and your doctor can see the pattern.

“You can’t overreact to one visit. You have to track over time and see a trend.”

Nick Napolitano, PV patient advocate
Hematocrit trackerTreatment target goal is under 45%
54%50%46%42%38% 45% goal JanMarMayJulSepNov
Example values for illustration only. Your goal and readings come from your care team.

What you’ll get

Six pages for every appointment

All six pages of the PV Toolkit fanned out, with the cover page, Know Your Options, Shape Your Care, in front
  1. Why track my symptoms?Common PV symptoms, what else to note, and a free symptom tracker from Blood Cancer United.
  2. Shaping your personalized treatment planLow risk vs. high risk, plus a plain-language guide to your labs.
  3. Treatment optionsPhlebotomy, aspirin, hydroxyurea, ropeginterferon, ruxolitinib and rusfertide, from our interview with Dr. Vaughn.
  4. Track, prepare, and askA lab tracker and the questions to bring to your care team.
  5. Your care team and supportWho belongs on your team, and where to find help with cost, trials and support.

Starts with My PV at a Glance, one page for your diagnosis, mutation, risk category and care team.

The program panel

A hematologist and a patient, in one conversation

Jennifer Vaughn, MD, MSPH

Jennifer Vaughn, MD, MSPH

Associate Professor of Hematology, The Ohio State University Comprehensive Cancer Center – The James

Hematologist focused on MPNs, including PV. Former community oncologist; published ASH education content on preventing blood clots in PV.

“Thankfully, most patients live for decades with the diseases, and so there are a lot of different considerations we need to have.”

Nick Napolitano

Nick Napolitano

PV Patient Advocate, Moderator, The Patient Story

Diagnosed with JAK2-positive PV in 2016 at age 37. Patient speaker and volunteer leader with Blood Cancer United’s Light The Night.

Program Partners

MPN Research Foundation

Founded by a PV patient, MPNRF directly connects patients, researchers, and clinicians while offering educational resources like the You and MPN series to help navigate care options.

Blood Cancer United

Thank you to Blood Cancer United for their partnership. They are here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.

Watch Dr. Vaughn’s program. Keep the toolkit for every appointment.

Free and on demand. The toolkit arrives by email.